Advertisement

Chinese Journal of Integrative Medicine

, Volume 11, Issue 3, pp 222–225 | Cite as

A clinical study of Safflower Yellow injection in treating coronary heart disease angina pectoris with Xin-blood stagnation syndrome

  • Zhang Qiong
  • Peng Jian-hua
  • Zhang Xiang-nong
Clinical Experiences

Abstract

Objective: To evaluate the clinical effect and safety of Safflower Yellow injection (SYI) in treating coronary heart disease angina pectoris (CHD-AP) with Xin-blood stagnation syndrome (XBSS).Methods: Adopted was the multi-centered, randomized, positive parallel controlled method, 448 patients with CHD-AP-XBSS were enrolled and divided into two groups, 336 in the tested group treated with SYI and 112 in the control group treated with Salvia injection by intravenous dripping once a day for 14 days, so as to observe the conditions of angina, electrocardiogram, and therapeutic effect on traditinal Chinese medicine (TCM) symptoms as well as the safety of the treatment.Results: The significantly effective rate and total effective rate in the tested group were 60.06% (194/323) and 91.02% (294/323) respectively; those in improvement of TCM symptoms were 40.18% (129/321) and 75. 23% (243/323) respectively, which were better than those in the control group (P<0.01).Conclusion: SYI Injection is effective and safe in treating CHD-AP-XBSS.

Key words

Safflower yellow injection coronary heart disease angina pectoris Xin-Blood stagnation syndrome 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Zheng XY. Guiding principle of clinical research on Chinese new drugs. 1st ed. Beijing: Chinese Publishing of Medical and Pharmaceutical Technique, 2002: 69–73.Google Scholar
  2. 2.
    Special Group of Clinical Nomenclature Standardization, International Association of Heart Diseases and WHO. Standard for nomenclature and diagnosis of ischemic heart disease. Chin J Cardiol 1981; 9(1): 75–76.Google Scholar
  3. 3.
    National Administration of Drugs Supervising and Managing. Technologic requirement for research of Chinese new drugs. 2000: 29–30.Google Scholar
  4. 4.
    Zheng QS, Sun RY, Chen ZY. Safety analysis on the regulation of minimal cases in clinical trial of new drugs. Chin J Clin Pharmacol Ther 2003; 8 (3): 354–355.Google Scholar
  5. 5.
    Zheng QS, Sun RY, Chen ZY. Discussion on the concise calculation and equivalent standard for sample assessment in new drug clinical trial. Chin New Drug J 2003;12 (5): 368–371.Google Scholar

Copyright information

© The Chinese Journal of Integrated Traditional and Western Medicine Press 2005

Authors and Affiliations

  1. 1.The National Clinical Base of Drug Research, Xiyuan HospitalChina Academy of Traditional Chinese MedicineBeijing
  2. 2.Deyuantang Pharmaceutical Ltd. Co.Shangxi
  3. 3.People’s Hospital of QingdaoChina

Personalised recommendations